Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Annie De Groot
AddedMar 31, 2024
UpdatedMay 31, 2026
Annie De Groot

Annie De Groot

Co-Founder & CEO, EpiVax Oncology

LinkedIn

Annie De Groot's Career

EpiVax Oncology
EpiVax Oncology

Providence, RI, US

Co-Founder & CEO· C-Suite · Management
Epivax
Epivax

Providence, RI, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Annie De Groot's Career

EpiVax Oncology
EpiVax Oncology
Pre-Seed$1.5M52017Providence, RI, US
Co-Founder & CEO· C-Suite · Management

Leadership at EpiVax Oncology

Daniel AdamsDaniel AdamsBoard Member
William MartinWilliam MartinCo-Founder
Gad BerdugoGad BerdugoCo-Founder

Similar to EpiVax Oncology

EpivaxEpivaxProvidence, RI, USVaccine Designest. 1998EpivaxProvidence, RI, US · est. 1998

EpiVax, a US-based immunology company, excels in computational immunology analysis.

Seed · $6.6M15
CancervaxCancervaxSanta Barbara, CA, USCancer Treatmentest. 2021CancervaxSanta Barbara, CA, US · est. 2021

CancerVAX Biotech: Santa Barbara-based medical firm innovating universal cancer treatments.

Seed · $500k13
AgilvaxAgilvaxAlbuquerque, NM, USImmunotherapies, Vaccinesest. 2011AgilvaxAlbuquerque, NM, US · est. 2011

Agilvax Inc: A biotech firm specializing in developing immunotherapies for cancer and targeted vaccines.

Series A · $8.3M11
OncoPrecisionOncoPrecisionNew York City, NY, USCancer Treatmentest. 2020OncoPrecisionNew York City, NY, US · est. 2020

Developing advanced tech for personalized cancer treatment and aiding in transformative therapy creation.

Seed · $4.2M37
Epivax
Epivax
Seed$6.6M151998Providence, RI, US
CEO· C-Suite · Management

Leadership at Epivax

Prof. Dr. Annie De GrootProf. Dr. Annie De GrootFounder

Similar to Epivax

EpiVax OncologyEpiVax OncologyProvidence, RI, USCancer Vaccinesest. 2017EpiVax OncologyProvidence, RI, US · est. 2017

EpiVax Oncology: A US-based biotech firm specializing in precision cancer immunotherapy vaccines.

Pre-Seed · $1.5M5
AgilvaxAgilvaxAlbuquerque, NM, USImmunotherapies, Vaccinesest. 2011AgilvaxAlbuquerque, NM, US · est. 2011

Agilvax Inc: A biotech firm specializing in developing immunotherapies for cancer and targeted vaccines.

Series A · $8.3M11
VaccinexVaccinexRochester, NY, USAntibodies, Vaccinesest. 1997VaccinexRochester, NY, US · est. 1997

US-based Vaccinex, Inc. develops therapeutic antibodies and vaccines for cancer, neurodegenerative diseases, and autoimmune disorders.

Public · $75.5M38
PathovaxPathovaxBaltimore, MD, USBiotechnology, Vaccinesest. 2014PathovaxBaltimore, MD, US · est. 2014

PathoVax, a Johns Hopkins biotech start-up, specializes in commercializing RGVax in bioscience.

Seed · $6M15

Annie De Groot's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to Annie De Groot

Dan LittmanDan LittmanBoard Member · PfizerFred RamsdellFred RamsdellCo-Founder · Sonoma BiotherapeuticsCarl JuneCarl JuneCo-Founder · Tmunity TherapeuticsLaurie GlimcherLaurie GlimcherCo-Founder · Quentis TherapeuticsAtul ButteAtul ButteFounder · PersonalisJeffrey BluestoneJeffrey BluestoneBoard Member · Parker Institute for Cancer Immunotherapy